Metagenomi Therapeutics (MGX)

Metagenomi Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances).

Download CSV

1.3M

Short interest

settlement 2026-10-15

6.3

Days to cover

-4.3 days vs prior

20.8%

Short share of volume

2026-11-02

1,997

Fails to deliver

settlement 2026-10-13

Wed 11 Nov

Next earnings

estimated date

$18K

Insider flow, 90 days

2 buys, 3 sells

As of 2026-11-02.

Short interest

FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSON

As of 15 October 2026, short interest in MGX is 1,292,216 shares, down 138,218 shares over the last month. Over the last 48 readings it ranged from 259,370 shares (31 October 2024) to 2,962,764 shares (30 April 2025). At the reported average volume of 206K shares a day that is 6.3 days to cover.

Embed this chart.The embed keeps its attribution line.

<iframe src="https://xoomar.com/embed/stocks/mgx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

Preview Dark previewAdd ?theme=dark to the src for a dark chart.

Settlement	Shares short	Change	Avg daily volume	Days to cover
2026-10-15	1,292,216	+1.6%	206,462	6.26
2026-09-30	1,271,863	-11.1%	120,626	10.54
2026-09-15	1,430,434	-0.3%	195,696	7.31
2026-08-31	1,435,524	-1.2%	135,848	10.57
2026-08-14	1,453,190	-2.7%	132,363	10.98
2026-07-31	1,493,337	-3.2%	148,142	10.08
2026-07-15	1,543,288	-8.4%	237,848	6.49
2026-06-30	1,684,034	-4.1%	144,636	11.64
2026-06-15	1,755,888	-4.1%	153,608	11.43
2026-05-29	1,831,424	+1.3%	198,963	9.20
2026-05-15	1,807,425	+1.1%	179,465	10.07
2026-04-30	1,787,777	-4.4%	180,696	9.89
2026-04-15	1,870,222	-13.7%	171,499	10.91
2026-03-31	2,167,525	+8.2%	213,560	10.15
2026-03-13	2,003,259	+3.7%	324,096	6.18
2026-02-27	1,931,219	-2.6%	159,800	12.09
2026-02-13	1,982,687	-18.2%	307,258	6.45
2026-01-30	2,423,284	+2.7%	249,636	9.71
2026-01-15	2,358,973	+6.8%	274,249	8.60
2025-12-31	2,208,088	+8.0%	358,977	6.15
2025-12-15	2,045,457	+27.1%	390,530	5.24
2025-11-28	1,609,444	+31.1%	361,178	4.46
2025-11-14	1,227,790	-12.4%	493,189	2.49
2025-10-31	1,402,015	-13.0%	991,247	1.41
2025-10-15	1,611,815	+8.1%	887,140	1.82
2025-09-30	1,490,834	+36.2%	818,694	1.82
2025-09-15	1,094,418	-23.2%	157,543	6.95
2025-08-29	1,424,336	-4.8%	187,250	7.61
2025-08-15	1,496,821	+7.6%	405,263	3.69
2025-07-31	1,391,173	+4.6%	796,982	1.75
2025-07-15	1,329,771	-10.1%	1,018,949	1.31
2025-06-30	1,479,598	-29.4%	836,361	1.77
2025-06-13	2,095,797	-1.7%	485,964	4.31
2025-05-30	2,132,291	-11.3%	253,629	8.41
2025-05-15	2,404,470	-18.8%	414,283	5.80
2025-04-30	2,962,764	+7.3%	290,754	10.19
2025-04-15	2,761,993	+3.4%	399,179	6.92
2025-03-31	2,670,946	+1.4%	478,104	5.59
2025-03-14	2,635,113	-0.7%	319,366	8.25
2025-02-28	2,654,240	+3.5%	468,900	5.66
2025-02-14	2,565,725	-2.7%	574,180	4.47
2025-01-31	2,635,799	+21.6%	2,820,774	1.00
2025-01-15	2,167,579	+6.0%	647,687	3.35
2024-12-31	2,045,705	+38.0%	1,540,229	1.33
2024-12-13	1,482,382	+446.0%	8,201,172	1.00
2024-11-29	271,482	-38.8%	535,547	1.00
2024-11-15	443,564	+71.0%	439,959	1.01
2024-10-31	259,370	-29.8%	288,324	1.00

Daily short volume

FINRA Reg SHO, the last 30 sessions. JSON

As of 2 November 2026, the short share of MGX volume is 20.8%, down 23.1 points over the last five sessions. Over the last 30 readings it ranged from 10.9% (30 October 2026) to 87.3% (23 October 2026). The latest reading is 27.4 points below the 30-session average of 48.3%, on 54K shares reported.

Date	Short volume	Total volume	Short share	Exempt
2026-11-02	11K	54K	20.8%	0
2026-10-30	3K	28K	10.9%	0
2026-10-29	28K	51K	54.1%	396
2026-10-28	34K	67K	50.5%	0
2026-10-27	49K	112K	43.8%	5,200
2026-10-26	52K	118K	43.9%	0
2026-10-23	46K	53K	87.3%	0
2026-10-22	9K	26K	34.4%	276
2026-10-21	33K	55K	59.6%	0
2026-10-20	18K	42K	42.0%	0
2026-10-19	37K	83K	45.1%	0
2026-10-16	55K	94K	58.6%	0
2026-10-15	146K	175K	83.3%	0
2026-10-14	107K	163K	65.8%	5,353
2026-10-13	84K	229K	36.6%	15,976
2026-10-12	39K	61K	63.6%	0
2026-10-09	23K	89K	25.5%	0
2026-10-08	153K	246K	62.0%	3
2026-10-07	107K	164K	65.1%	0
2026-10-06	58K	83K	68.9%	85
2026-10-05	54K	101K	53.9%	0
2026-10-02	43K	92K	46.7%	0
2026-10-01	43K	85K	50.0%	0
2026-09-30	44K	79K	56.1%	0
2026-09-29	18K	35K	50.7%	0
2026-09-28	22K	62K	35.3%	0
2026-09-25	6K	28K	23.3%	397
2026-09-24	31K	66K	46.8%	0
2026-09-23	18K	51K	35.7%	0
2026-09-22	23K	83K	27.4%	0

Fails to deliver

SEC, the last 30 settlement dates with a fail. JSON

As of 13 October 2026, the fails-to-deliver balance in MGX is 1,997 shares, up 1,994 shares over the last settlement date. Over the last 30 readings it ranged from 3 shares (22 September 2026) to 22,151 shares (21 August 2026). The latest reading sits at the bottom of that range.

Settlement	Shares failed	Price	Value
2026-10-13	1,997	$1.02	$2K
2026-09-22	3	$1.12	$3
2026-09-18	5,732	$1.13	$6K
2026-09-10	2,024	$1.15	$2K
2026-09-08	13,829	$1.17	$16K
2026-09-04	12,000	$1.16	$14K
2026-09-03	12,000	$1.16	$14K
2026-08-28	9,107	$1.21	$11K
2026-08-27	3,636	$1.22	$4K
2026-08-24	14,539	$1.23	$18K
2026-08-21	22,151	$1.20	$27K
2026-08-13	6,741	$1.22	$8K
2026-08-06	1,901	$1.22	$2K
2026-07-31	2,939	$1.22	$4K
2026-07-27	6,761	$1.21	$8K
2026-07-24	4,881	$1.22	$6K
2026-07-07	9,418	$1.25	$12K
2026-07-01	408	$1.19	$486
2026-06-30	4,328	$1.20	$5K
2026-06-29	6,166	$1.25	$8K
2026-06-26	6,471	$1.19	$8K
2026-06-25	13,070	$1.20	$16K
2026-06-24	13,970	$1.24	$17K
2026-06-23	10,480	$1.19	$12K
2026-06-22	141	$1.20	$169
2026-06-05	2,793	$1.33	$4K
2026-06-03	2,300	$1.33	$3K
2026-05-27	2,859	$1.36	$4K
2026-05-26	3,114	$1.35	$4K
2026-05-22	3,963	$1.31	$5K

Insider trades

SEC Form 4, newest first. JSON

Over the last 90 days MGX insiders reported 2 open-market buys ($23K) against 3 sells ($5K), so the dollar flow leans toward buying. Latest filing: Reid Laurence (Director) on 2026-09-09.

Date	Insider	Title	Type	Shares	Price	Value	Owned after
2026-09-09	Reid Laurence	Director	Buy	117	$1.18	$138	20K
2026-09-09	Reid Laurence	Director	Buy	20K	$1.17	$23K	20K
2026-09-08	Wein Matthew	See Remarks	Sell	358	$1.16	$415	126K
2026-09-08	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.16	$2K	207K
2026-09-08	Irish Jian	See Remarks	Sell	2K	$1.16	$2K	375K
2026-06-05	Wapnick Pamela	Chief Financial Officer	Sell	3K	$1.30	$4K	208K
2026-06-05	Wein Matthew	See Remarks	Sell	558	$1.30	$725	126K
2026-06-05	Irish Jian	See Remarks	Sell	4K	$1.30	$5K	378K
2026-04-01	Wein Matthew	See Remarks	Grant	11K	$0.00	$0	126K
2026-04-01	Wapnick Pamela	Chief Financial Officer	Grant	24K	$0.00	$0	211K
2026-04-01	Irish Jian	See Remarks	Grant	46K	$0.00	$0	380K
2026-03-05	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.60	$3K	187K
2026-03-05	Wein Matthew	See Remarks	Sell	482	$1.60	$771	115K
2026-03-05	Irish Jian	Chief Executive Officer	Sell	2K	$1.60	$3K	334K
2025-12-05	Thomas Brian C.	Director	Sell	4K	$1.77	$7K	2.5M
2025-12-05	Wein Matthew	See Remarks	Sell	199	$1.77	$353	115K
2025-12-05	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.77	$3K	189K
2025-12-05	Irish Jian	Chief Executive Officer	Sell	2K	$1.77	$3K	564K
2025-12-05	Irish Jian	Chief Executive Officer	Gift	228K	$0.00	$0	335K
2025-12-01	Wapnick Pamela	Chief Financial Officer	Grant	120K	$1.60	$192K	191K
2025-12-01	Wein Matthew	See Remarks	Grant	96K	$1.60	$154K	115K
2025-12-01	Irish Jian	Chief Executive Officer	Grant	211K	$1.60	$338K	565K
2025-12-01	Irish Jian	Chief Executive Officer	Grant	38K	$1.60	$60K	354K
2025-09-05	Thomas Brian C.	Director	Sell	3K	$1.81	$5K	2.5M
2025-09-05	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.81	$3K	71K
2025-09-05	Wein Matthew	See Remarks	Sell	199	$1.81	$360	19K
2025-09-05	Irish Jian	Chief Executive Officer	Sell	2K	$1.81	$3K	317K
2025-06-06	Irish Jian	See Remarks	Sell	6K	$1.75	$11K	316K
2025-06-06	Thomas Brian C.	Chief Executive Officer	Sell	11K	$1.75	$19K	2.5M
2025-06-06	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.75	$3K	72K
2025-06-06	Noonberg Sarah B.	Chief Medical Officer	Sell	5K	$1.75	$9K	109K
2025-06-06	Wein Matthew	See Remarks	Sell	199	$1.75	$348	17K
2025-04-01	Noonberg Sarah B.	Chief Medical Officer	Grant	14K	$0.00	$0	114K
2025-04-01	Wein Matthew	See Remarks	Grant	4K	$0.00	$0	13K
2025-04-01	Wein Matthew	See Remarks	Grant	4K	$0.00	$0	17K
2025-04-01	Irish Jian	See Remarks	Grant	23K	$0.00	$0	322K
2025-04-01	Thomas Brian C.	Chief Executive Officer	Grant	32K	$0.00	$0	2.5M
2025-04-01	Wapnick Pamela	Chief Financial Officer	Grant	14K	$0.00	$0	74K
2025-03-05	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.87	$3K	60K
2025-03-05	Wein Matthew	See Remarks	Sell	930	$1.87	$2K	9K
2024-12-05	Wapnick Pamela	Chief Financial Officer	Sell	2K	$1.86	$3K	61K
2024-09-05	Wapnick Pamela	Chief Financial Officer	Sell	6K	$2.88	$18K	63K
2024-04-01	Thomas Brian C.	Chief Executive Officer	Grant	119K	$0.00	$0	2.5M
2024-04-01	Delaney Simren	See Remarks	Grant	7K	$0.00	$0	94K
2024-04-01	Harnest Simon	See Remarks	Grant	12K	$0.00	$0	123K
2024-04-01	Noonberg Sarah B.	Chief Medical Officer	Grant	58K	$0.00	$0	100K
2024-04-01	Wapnick Pamela	Chief Financial Officer	Grant	69K	$0.00	$0	69K
2024-04-01	Wein Matthew	See Remarks	Grant	10K	$0.00	$0	10K
2024-04-01	Borges Luis	Chief Scientific Officer	Grant	69K	$0.00	$0	69K
2024-04-01	Irish Jian	See Remarks	Grant	70K	$0.00	$0	299K
2024-02-13	Bernales Sebastian	Director	Conversion	1.9M	price not stated in the filing	not stated	1.9M
2024-02-13	Bernales Sebastian	Director	Conversion	513K	price not stated in the filing	not stated	770K
2024-02-13	Bayer World Investments B.V.	TenPercentOwner	Conversion	510K	price not stated in the filing	not stated	4.1M
2024-02-13	Bayer World Investments B.V.	TenPercentOwner	Conversion	1.8M	price not stated in the filing	not stated	1.8M
2024-02-13	Bayer World Investments B.V.	TenPercentOwner	Conversion	1.2M	price not stated in the filing	not stated	3.0M
2024-02-13	Bayer World Investments B.V.	TenPercentOwner	Conversion	590K	price not stated in the filing	not stated	3.5M
2024-02-13	Novo Holdings A/S	TenPercentOwner	Conversion	839K	price not stated in the filing	not stated	939K
2024-02-13	Novo Holdings A/S	TenPercentOwner	Buy	800K	$15.00	$12.0M	1.7M
2024-02-09	Novo Holdings A/S	TenPercentOwner	Buy	100K	$10.25	$1.0M	100K

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

Large holders (13D and 13G)

One row per reporting person with its latest filing, newest first. JSON

1 holder reports 5% or more of MGX in its latest filing, on Schedule 13G (passive). The holder is Thomas Brian C. at 7.3% of the class (2,762,142 shares), filed 2026-09-10 for an event on 2026-06-30.

Filed	Form	Holder	Shares	Of class	Event
2026-09-10	13G	Thomas Brian C.individual	2.8M	7.3%	2026-06-30

13F holders

Tracked managers holding MGX at their latest 13F. JSON

4 of the 30 tracked managers held MGX at their latest 13F, $1.7M in total at quarter-end prices. Renaissance Technologies is the largest at $883K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 2 cut.

Fund	Quarter	Shares	Value	Of portfolio	Change in shares
Renaissance Technologies	2026-06-30	742K	$883K	0.00%	-46K
Two Sigma Investments	2026-06-30	514K	$611K	0.00%	+17K
Millennium Management	2026-06-30	114K	$136K	0.00%	-56K
Citadel Advisors	2026-06-30	18K	$21K	0.00%	+858

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

What this page is

Metagenomi Therapeutics in the regulatory record

Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.

Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.

This page follows Metagenomi Therapeutics (MGX), SEC CIK 1785279, listed on Nasdaq, classified by the SEC as biological products, (no diagnostic substances). The cross-market tables live on the short interest and insider transactions hubs.

Source and updates

Short interest: FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
Daily short volume: FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
Fails to deliver: SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
Large holders: SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-10.JSON and CSV
13F holders: SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
Earnings dates: SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-05-11.JSON and CSV
Insider trades: SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-09.JSON and CSV
Company record: EDGAR filing index for CIK 1785279Ticker, name and exchange from the SEC's company list, refreshed weekly.
Rate limits: 10 requests a minute without a key, 30 with a free key from a free account.

How to read it

Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.

Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.

Other companies the SEC classifies as biological products, (no diagnostic substances)

Other company pages

Datasets

Frequently Asked Questions

How much of MGX is sold short?

1,292,216 shares were held short at the 2026-10-15 settlement, 6.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.

What is MGX's daily short volume?

On 2026-11-02, 11,200 of the 53,743 MGX shares reported to FINRA were sold short, 20.8% of the day's reported volume. Short volume is a flow for one day, not a position.

Does MGX have fails to deliver?

The SEC's latest file shows 1,997 MGX shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.

Are MGX insiders buying or selling?

Over the last 90 days MGX insiders reported 2 open-market buys ($23K) against 3 sells ($5K), so the dollar flow leans toward buying. Latest filing: Reid Laurence (Director) on 2026-09-09.

Who owns 5% or more of MGX?

1 holder reports 5% or more of MGX in its latest filing, on Schedule 13G (passive). The holder is Thomas Brian C. at 7.3% of the class (2,762,142 shares), filed 2026-09-10 for an event on 2026-06-30.

Which tracked 13F managers own MGX?

4 of the 30 tracked 13F managers held MGX shares at their latest filing, $1.7M in all. The largest: Renaissance Technologies (742K shares, $883K), Two Sigma Investments (514K shares, $611K), Izzy Englander's Millennium Management (114K shares, $136K), Ken Griffin's Citadel Advisors (18K shares, $21K).

Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.